SOR C13 / Soricimed - LARVOL DELTA

A Phase I Study of SOR-C13 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=11 | Completed | Sponsor: M.D. Anderson Cancer Center | Recruiting ➔ Completed | N=36 ➔ 11

Enrollment change • Metastases • Trial completion • Gastrointestinal Cancer • Genito-urinary Cancer • Hepatology • Oncology • Ovarian Cancer • Pancreatic Cancer • Prostate Cancer • Refractory Ovarian Cancer • Solid Tumor • TRPV6

SOR-C13 in Treating Patients With Advanced Refractory Solid Tumors (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: M.D. Anderson Cancer Center | Trial completion date: Aug 2022 ➔ Aug 2023 | Trial primary completion date: Aug 2022 ➔ Aug 2023

Trial completion date • Trial primary completion date • Gastrointestinal Cancer • Genito-urinary Cancer • Hepatology • Oncology • Ovarian Cancer • Pancreatic Cancer • Prostate Cancer • Refractory Ovarian Cancer • Solid Tumor • TRPV6

[VIRTUAL] A phase Ib study on a TRPV6-inhibitor, SORC13 in patients with advanced solid tumours (ESMO 2020) - P1 | "Funding: NCI. Clinical trial identification: NCT03784677."

Clinical • P1 data • Genito-urinary Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Prostate Cancer • Solid Tumor

[VIRTUAL] Soricimed Biopharma Inc. (BIO 2021) - "The Company’s lead drug candidate, SOR-C13, is a first-in-class selective inhibitor of TRPV6 - a calcium channel over-expressed by solid tumour cancers...Soricimed recently launched a collaboration to develop a targeted peptide receptor radiotherapy (PRRT). Finally, Soricimed has successfully constructed peptide-drug conjugates (PDCs) that specifically target cancer cells by way of binding to TRPV6."

Gastrointestinal Cancer • Hepatology • Oncology • Ovarian Cancer • Pancreatic Cancer • Solid Tumor

Soricimed Announces Completion of Second Patient Cohort in Investigator-Initiated Phase 1b Clinical Trial of Oncology Drug Candidate SOR-C13 (Canada Newswire) - "Soricimed Biopharma Inc...announced that MD Anderson Cancer Center ('MDACC') has completed patient dosing in the second cohort of its Phase 1b investigator-initiated trial of Soricimed's lead drug candidate, SOR-C13....The trial is proceeding as designed and recruitment for cohort 3 is currently underway."

Trial status • Oncology • Solid Tumor

Soricimed to Investigate the Potential Benefit of SOR-C13 in the Treatment of COVID-19 (Canada Newswire) - "Soricimed Biopharma Inc....today announced that it will investigate the potential therapeutic role its cancer drug candidate, SOR-C13, can play in helping relieve or prevent severe immune response to the SARS CoV-2 virus....Early data suggest that SOR-C13 could interfere with the interaction of the virus with the ACE2 receptor, and stop the entrance of SARS-CoV-2 into healthy cells resulting in the virus' inability to reproduce....The National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) is supporting Soricimed with advisory services and research and development funding for preclinical testing. In parallel, Soricimed is looking to initiate a Phase 2 clinical trial."

Financing • Preclinical • Infectious Disease • Novel Coronavirus Disease

The central role of NFAT signalling in the mechanism of action of the TRPV6 oncochannel inhibitor and clinical candidate SOR-C13 (AACR 2018) - "These results highlight NFAT signalling in the mechanism of action of SOR-C13. The impact of SOR-C13 on the expression of genes involved in resistance to apoptosis, proliferation, metastasis and angiogenesis as well as on the expression of immune cytokines and transcription factors in multiple cancer cells, makes SOR-C13 an attractive, novel anti-cancer drug."

Clinical • Breast Cancer

Methylome profiling of young adults with depression supports a link with immune response and psoriasis. (PubMed, Clin Epigenetics) - "Our data suggests an immune component to the aetiology of depression in at least a small subgroup of cases, consistent with the accumulating evidence supporting a relationship between inflammation and depression. Additionally, DNA methylation changes at key loci, detected in saliva, may represent a valuable tool for identifying at-risk subjects."

Clinical • Journal • Alzheimer's Disease • CNS Disorders • Depression • Dermatology • Dermatopathology • Immunology • Mood Disorders • Psoriasis

Safety and Tolerability Study of SOR-C13 in Subjects With Advanced Cancers Commonly Known to Express the TRPV6 Channel (clinicaltrials.gov) - P1; N=23; Completed; Sponsor: Soricimed Biopharma Inc; Recruiting ➔ Completed; N=30 ➔ 23

Enrollment change • Trial completion • Biosimilar • Oncology

YEAST PHENOMIC ANALYSIS OF RPL12 EPISTASIS IN THE RESCUE OF F670DEL-YOR1 MISFOLDING (NACFC 2019) - "Other GO-enriched and non-GO-enriched genes in both deletion enhancing and suppressing interaction categories were additionally informative about biological processes that alternately promote or impede deltaF biogenesis. (Supported by CFF (SORSCH13XXO; HARTMA155G0) and NIH (R01HL136414).)"

EPISTATIC EFFECTS OF COMPLEX ALLELES ON CYSTIC FIBROSIS PHENOTYPE – A PROTEIN TRANSLATIONAL PERSPECTIVE (NACFC 2019) - "Epistatic interactions such as these may have greater impact on CF disease severity and efficacy of pharmacologic intervention than previously appreciated. (Supported by CFF (SORSCH13XXO, IGNATO17XXO OLIVER17F0), Muko e.V Germany (1603), DFG (1805), NIH USA (R01HL138414).)"

PARTIAL RESCUE OF G542X- AND W1282X-CFTR IS ACHIEVED FOLLOWING SUPPRESSION OF SPECIFIC RIBOSOMAL COMPONENTS (NACFC 2019) - "Taken together, our results establish relevance of the yeast phenomics model and indicate specific ribosomal proteins – Rpl8 or Rpl12 in particular – should be considered as novel therapeutic targets for overcoming CFTR PTCs. (Supported by CFF (OLIVER17F0; IGNATO17XXO; SORSCH13XXO; HARTMA16G0), Burroughs Wellcome Fund (2018 CRTG) and NIH (R01HL136414).)"

SOR-C13 in Treating Patients With Advanced Refractory Solid Tumors (clinicaltrials.gov) - P1; N=36; Recruiting; Sponsor: M.D. Anderson Cancer Center; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open